Showing 1 - 10 of 199
We investigate entry in a dynastic entrepreneurship (overlapping generations) environment created by employee spinoffs …, optimal entry of original firms and all subsequent employee spinoffs is achieved, despite the fact that the original firm can … increases the rate of spinoffs from original firms. Indeed, if employers have all the bargaining power vis-à-vis their employees …
Persistent link: https://www.econbiz.de/10010531845
This paper proposes a novel approach to evaluate location decisions for public facilities. The approach addresses, not … only the standard distance-minimizing problem, but also the endogenous location decisions of individuals. To do so, I …, commutes to work and public facilities, as well as public facility characteristics. The latter includes a facility’s location …
Persistent link: https://www.econbiz.de/10012581971
We derive equilibrium incentives to use comparative advertising that pushes up own brand perception and pulls down the brand image of targeted rivals. Data on content and spending for all TV advertisements in OTC analgesics enable us to construct matrices of dollar rival targeting and estimate...
Persistent link: https://www.econbiz.de/10011307083
This paper studies the effects of price regulation and parallel imports in the on-patent pharmaceutical market. In a theory model where the producer price is subject to bargaining between the brand-name producer and a distributor, we show that the effects of stricter price regulation crucially...
Persistent link: https://www.econbiz.de/10011307132
There were no innovations in chemotherapy for myeloma patients during the period 1977-1997, but there have been several important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma patients using both time-series U.S. data and...
Persistent link: https://www.econbiz.de/10010328754
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010328831
There are two types of prescription drug cost offsets. The first type of cost offset—from prescription drug use—is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset—the cost offset...
Persistent link: https://www.econbiz.de/10012018250
the profits are sufficient to cover the entry costs. The other brand-name drug has already lost its patent and faces … profits to the patent-holding firm, making entry of the new drug treatment least likely. Surprisingly, we find that GRP …
Persistent link: https://www.econbiz.de/10010263999
We study the relationship between regulatory regimes and pharmaceutical firms' pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called index pricing for a sub-sample of off-patent pharmaceuticals, replacing the existing price...
Persistent link: https://www.econbiz.de/10010264178
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...
Persistent link: https://www.econbiz.de/10010274913